Research Article

Intervening TNF-α via PPARγ with Gegenqinlian Decoction in Experimental Nonalcoholic Fatty Liver Disease

Yun-liang Wang, Li-juan Liu, Wei-han Zhao, and Jun-xiang Li

Gastroenterology Department, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, China

Correspondence should be addressed to Jun-xiang Li; lijunxiang1226@163.com

Received 2 August 2014; Revised 16 November 2014; Accepted 7 December 2014

Academic Editor: Mohammad Ahmad Al-Shatouri

Copyright © 2015 Yun-liang Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This paper is to explore the effect and mechanism of Gegenqinlian decoction on experimental nonalcoholic fatty liver disease (NAFLD) in vivo and in vitro. The final aim is to make clear whether Gegenqinlian decoction would impact NAFLD through improving PPARγ to suppress inflammation and regulate lipid. The data in this research suggested that Gegenqinlian decoction is a potent way to manage NAFLD through improving PPARγ to regulate lipid and suppress inflammation.

1. Background

Nonalcoholic fatty liver disease (NAFLD) is a kind of disease ranging from simple hepatic steatosis to nonalcoholic steatohepatitis (NASH) and irreversible cirrhosis [1]. The prevalence of NAFLD has risen rapidly in parallel with dramatic rise in obesity, diabetes [2, 3], hypertension, and dyslipidaemia and NAFLD is now regarded as the liver manifestation of metabolic syndrome (Mets). Up till now, the pathogenesis and progression of NAFLD are not yet fully understood; the proven therapeutic trails are still in improving [4, 5]. Some researchers approve the “2-hit” hypothesis on the NAFLD pathogenesis. Briefly, the “first hit” involves hepatic triglyceride accumulation, or steatosis. The “second hit” usually links inflammatory cytokines and oxidative stress and so forth. As concerned, hepatic triglyceride accumulation can occur as a result of increased fat synthesis, increased fat delivery, decreased fat export, and/or decreased fat oxidation [6]. Inflammatory cytokines, such as TNF-α, IL-6, and IL-8, are involved in the second hit stage, mediate steatohepatitis in patients with NAFLD [7], and can be regulated by PPARγ, which is not only related to anti-inflammatory effects, but also close to improving insulin resistance [8].

Giving an effective therapeutic method for NAFLD/NASH to prevent future disease is of priority. Till now, intervention for NAFLD remains mainly through lifestyle modifications and nonpharmacological treatment. Hence, finding a new approach to NAFLD is in urgent need.

Chinese herbal medicine (CHM) has been traditionally used in China and other parts of Asian countries for thousands of years and is now spreading worldwide. A special and basic feature of Chinese medicine is the use of a formula containing several herbs (mixed as a cocktail) to ameliorate a series of abnormalities syndrome related to a certain disease. Herbal extracts contain multiple natural compounds that can aim to different targets via various pathological pathways involved in the disease, providing therapeutic effects via a spectrum of actions. Gegenqinlian decoction (GGQLD), a classical formula from Treatise on Febrile Diseases, is one of the well-known traditional Chinese medicines, which consists of Kudzu root, Rhizoma coptidis, Scutellaria baicalensis Georgi, and Main licorice. It is widely used to treat diarrhea. In previous studies, we have found that Gegenqinlian decoction can both improve diabetes [9, 10] and play an anti-inflammatory effect based on the compounds included [11–13], in which glucose and lipid metabolism disorder and inflammatory reaction play vital roles as in NAFLD. Hence, under the guidance of traditional Chinese medicine theory “same treatment for different diseases,” we propose a hypothesis that Gegenqinlian decoction could intervene and improve NAFLD by a multitargets solution.
2. Materials and Methods

2.1. Preparation of GGQLD and Rosiglitazone. GGQLD granules were provided by Pharmacy Department of Dongfang Hospital, Beijing University of Chinese Medicine (Beijing, China). The GGQLD granules contain equal weights of the ingredients of the Gegenqinlinian formula: *Kudzu root* 24 grams, *Rhizoma coptidis* 9 grams, *Scutellaria baicalensis* Georgii 9 grams, and *Main licorice* 6 grams. Rosiglitazone was purchased from Sigma, USA.

2.2. Animals and Treatment. Male Sprague-Dawley (SD) rats purchased from Sigma, USA. They were housed on a light/dark cycle under constant temperature (22 ± 2°C) with ad libitum access to standard chow diet (n = 6) or a high-fat diet (HFD, 34% fat, 19% protein, and 47% carbohydrate by energy composition) (n = 6) for 8 weeks to induce NAFLD. Tissue samples from 3 to 5 rats were prepared and stained after the experiment.

2.3. Cell Model Establishment and Intervention. HepG2 cells were cultured in Dulbecco’s Modified Eagle’s Medium (Gibco, USA) supplemented with 10% fetal bovine serum (FBS), penicillin (100 units/mL), and streptomycin (100 μg/mL) at 37°C under 5% CO₂, in a 95% humidified atmosphere. For the cell model establishing [14], palmitic and oleic acid 0.1M stock solutions were prepared by dissolving free acid 0.1M stock solutions were prepared by dissolving free fat acid (FFA) in DMSO (with a final concentration less than 0.1%). The cells were exposed to a mixture of exogenous 500 μM FFA in molar ratio 1:2 palmitic:oleic acid for 24 h. Since albumin concentration is an important factor in determining the concentration of available FFA, 1%BSA for the final concentration was considered. For the intervention, different concentrations of GW9662 and PPARγ selective agonist rosiglitazone [15] (Sigma, USA) were prepared and intervened together with FFA.

2.4. Determination of Metabolic Parameters: Liver Enzymes in Rats. At the end of treatment, animals were anesthetized using 4% chloral hydrate after a 12 h overnight fast; blood samples were collected from the abdominal aorta of rats. Fasting serum triglycerides (TGs), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were analyzed using Enzyme-linked immunosorbent assay (ELISA) (Bio Sino, Beijing, China). Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were also determined by ELISA (Bio Sino, Beijing, China).

2.5. Histological Analysis in Rats. A fresh liver tissue was fixed with 10% formaldehyde solution. Paraffin sections were used to Haematoxylin and Eosin (H&E) staining (Zeping, Beijing, China). Frozen sections were stained with Oil Red O (Sigma-Aldrich). Both staining methods were used to investigate the architecture of the liver and hepatic lipid droplets. Stained H&E and Oil Red O (ORO) slides were visualized with the Olympus microscope, and images were captured with Olympus digital camera (BX40, Beijing, China) using NIS Element SF 4.00.06 software (Beijing, China). For each group, liver samples from 3 to 5 rats were prepared and stained.

2.6. ELISA for Tumor Necrosis Factor-α (TNF-α) in Serum, Liver Tissue, and Cell Culture Media. After blood samples were collected, serum tumor necrosis factor-α (TNF-α) was tested by using rat ELISA kits (Boster Bio-Engineering, Wuhan, China). Liver was collected and washed by ice-cold PBS and then stored at −80°C for subsequent histological and molecular assays. Frozen liver tissue (0.5 g) was homogenized in 1 mL lysis buffer containing 150 mM NaCl, 1 mM PMSF, 10% glycerol, and the complete protease inhibitor cocktail (Roche, USA). The supernatant was collected for analysis of TNF-α using rat ELISA kits (Boster Bio-Engineering, Wuhan, China).

The TNF-α released in the culture media was determined by ELISA (Boster Bio-Engineering, Wuhan, China) according to manufacturer’s instructions. Cells were cultured and treated as previously described. The culture media were collected after 24 h, possible contamination of cellular fractions was eliminated by centrifugation, and the test was performed in cell-free supernatant.

2.7. Western Blotting to Detect PPARγ. Proteins in liver tissue homogenate were extracted using ice-cold tissue lysis buffer. Protein concentration was determined using a BCA protein assay kit. Samples were separated by 10% SDS-PAGE and transferred onto polyvinylidene difluoride membranes. The membranes were immunoblotted with primary antibodies that recognize PPARγ (1:2000) and GAPDH (1:20000) (TDY Biotech, Beijing, China). Peroxidase-conjugated secondary antibodies and an ECL detection system were used according to routine methods. The intensities of the protein bands were analyzed using Gel-Pro 3.2 software. GAPDH protein was used as the internal control to normalize the protein loading.

2.8. Real-Time Polymerase Chain Reaction for PPARγ mRNA Expression. Reverse transcription was performed with 1 μg of total RNA per 12 μL reaction using a standard cDNA Synthesis Kit (Takara, Japan). The real-time PCR primer
sequences for target genes were as follows: PPARγ, forward 5′-TACCACGTTGATTTCCT-3′ and reverse 5′-GCTCTACTTTGATCGACT-3′; GAPDH, forward 5′-TGGAGTCTACTGGCGTCTT-3′ and reverse 5′-TGTCCATATTCTCCTGATTCA-3′ (CWbio, Beijing, China). For each real-time PCR, the typical thermal cycling conditions included an initial activation step at 95°C for 5 min, 45 cycles of amplification, and a final melting curve (55–95°C).

2.9. Determination of Intracellular Fat Content: Oil Red O Staining and Quantifying. Cells were fixed and stained with Oil Red O and then washed by distilled water until the extracellular oil red is rinsed clean. The intracellular fats then trickle out after the rupture of cell membrane with 100% isopropyl alcohol. After shocks, OD values were read and analyzed by ELISA.

2.10. Data Analysis. All data are expressed as the mean ± SD unless otherwise indicated. Data were analyzed by using one-way ANOVA and a post hoc test. Differences were considered to be statistically significant at P < 0.05.

3. Results

3.1. Effect of Gegenqinlian Decoction on Lipid Metabolism and Liver Enzymes in HFD Rats. All animals tolerated the experimental procedures well, and no deaths occurred during the study. Serum ALT [(36.10 ± 3.92 U/L)] and AST [(425.85 ± 13.84 U/L)] concentrations in HFD fed rats were significantly higher than those in chow fed rats [(19.27 ± 3.36) U/L in ALT, (298.10 ± 5.13) U/L in AST, P < 0.01, resp.]. Both the GGQLDL [(28.20 ± 3.01) U/L in ALT, (291.24 ± 22.36) in AST] and GGQLDH [(24.98 ± 1.55) U/L in ALT, (206.68 ± 20.48) in AST] treatments significantly attenuated the elevated ALT and AST (P < 0.01), together with rosiglitazone [(27.98 ± 3.14) U/L in ALT, (243.48 ± 26.52) in AST, versus HFD, P < 0.01, resp.] (Figure 1). HDL-C levels rose in GGQLDL [(1.90 ± 0.10 mmol/L)] group compared to HFD model group [(0.95 ± 0.04 mmol/L, P < 0.01)]. Meanwhile, GGQLDH [(0.98 ± 0.15 mmol/L)] also decrease LDL-C concentrations, but the statistical significance was not achieved (P > 0.01), whereas GGQLDL [(0.79 ± 0.09 mmol/L)] and rosiglitazone [(0.87 ± 0.22 mmol/L)] groups significantly decreased LDL-C level compared to HFD model group [(1.07 ± 0.20 mmol/L, P < 0.01, resp.)]. Both GGQLDL [(1.94 ± 0.39 mmol/L)] and GGQLDH [(1.53 ± 0.11 mmol/L)] treatments significantly attenuated the elevated TC [(2.81 ± 0.79 mmol/L in HFD, P < 0.01, resp.)]. Rosiglitazone not only decreased serum TC [(1.94 ± 0.12 mmol/L)], but also TG [(0.59 ± 0.02) mmol/L versus (0.67 ± 0.04) mmol/L in HFD, P < 0.01] (Figure 2).

3.2. GGQLD Improved Histopathology in Rats. The photomicrographs of the H&E stain also displayed steatosis and ballooning degeneration and evident infiltration with inflammatory cells in the intercellular substance, causing conspicuous swelling of the cell and cytoplasmic vacuolation as shown in Figure 3(b). The treatment of HFD rats with GGQLDs and rosiglitazone reduced fat deposits in liver (Figures 3(c), 3(d), and 3(e)) and the GGQLDs showed histological features similar to the chow group with little steatosis as shown in Figures 3(c) and 3(d). Oil Red O staining on frozen liver sections showed few lipid droplets were detected in the liver sections from the chow group (Figure 4(a)). Compared with that of HFD fed model rats (Figure 4(b)), both GGQLDs and rosiglitazone...
Figure 2: Effect of GGQLD on the concentration of triglyceride (TG), total cholesterol (TC), high-density lipoprotein (HDL), and low-density lipoprotein (LDL). (a) HDL levels in serum; (b) LDL levels in serum; (c) TG levels in serum; (d) TC levels in serum. In the in vivo study, data are means ± SD; n = 6 rats/group. *P < 0.05, **P < 0.01 versus chow; *P < 0.05, **P < 0.01 versus HFD.

3.3. Effects of GGQLD on Serum and Liver TNF-α. Serum and liver TNF-α were determined in chow fed rats and HFD rats treated with saline, GGQLDL, GGQLDH, or rosiglitazone, respectively. As shown in Figures 5(a) and 5(b), HFD feeding significantly increased TNF-α compared with chow fed rats [(228.05 ± 26.85) pg/mL in HFD versus (87.59 ± 53.23) pg/mL in chow, in serum, P < 0.01; (603.68 ± 45.57) pg/mL in HFD versus (459.50 ± 12.53) pg/mL in chow, in liver, P < 0.01]. GGQLDL [(81.41 ± 15.39) pg/mL in serum, (525.55 ± 19.77) pg/mL in liver], GGQLDH [(98.42 ± 26.03) pg/mL in serum, (525.05 ± 58.87) pg/mL in liver], and rosiglitazone [(171.23 ± 18.63) pg/mL in serum, (533.30 ± 24.14) pg/mL in liver] were capable of significantly inhibiting HFD-induced elevated TNF-α both in serum and in liver (versus HFD, P < 0.01, resp.) (Figures 5(a) and 5(b)).

3.4. GGQLD Regulated PPARγ Expression in HFD-Induced NAFLD Rats. We investigated whether GGQLD had a regulatory effect on PPARγ expression. As shown in Figure 6, the PPARγ level was significantly decreased on HFD group (P < 0.01, versus chow group). More remarkably, GGQLDs and rosiglitazone produced a dramatically improved effect on PPARγ level (versus HFD group, P < 0.01, resp., Figure 6).

3.5. Validation of GGQLD on PPARγ Gene Expression with Real-Time PCR. In order to confirm the results of effects of GGQLD on liver PPARγ protein expression, the expression of PPARγ gene was measured. The gene expression in HFD rat group decreased compared to chow group, but without a statistical significance (Figure 7). Remarkably, GGQLDs
and rosiglitazone made a great contribution to increasing PPARγ gene expression (versus HFD group, \( P < 0.01 \), resp., Figure 7).

3.6. Cell Release of TNF-\( \alpha \) in the Culture Medium. Compared with the model group \([(203.83 \pm 39.64) \text{ pg/mL}]\), the production of TNF-\( \alpha \) was evaluated in GW9662 10 mmol/L group \([(212.17 \pm 40.59) \text{ pg/mL}, P > 0.05]\), while the TNF-\( \alpha \) decreased in rosiglitazone 2 mmol/L group \([(97.17 \pm 2.93) \text{ pg/mL}, P < 0.01]\) (Figure 8).

3.7. Determination of Intracellular Fat Content In Vitro. The intracellular lipid droplets content was analyzed by reading OD values; lipid droplets levels were increased significantly in groups with different concentrations of GW9662 compared with the model group \((P < 0.05)\) (Figure 9).

4. Discussion

Nonalcoholic fatty liver disease (NAFLD), a multifactorial disorder with contribution of a variety of genetic and environmental factors, is considered to be closely associated with hepatic metabolic disorders, resulting in overaccumulation of fatty acids/triglycerides and cholesterol. The presence of steatosis is tightly associated with chronic hepatic inflammation [16], an effect in part mediated by activation of the Ik\( \kappa \)-b/NF-\( \kappa \)B signaling pathway. In murine models of high-fat diet induced steatosis, increased NF-\( \kappa \)B activity is associated with elevated hepatic expression of inflammatory cytokines such as TNF-\( \alpha \) and activation of Kupffer cells [16]. TNF-\( \alpha \), a proinflammatory cytokine that is activated by the reactive oxygen species created by lipid peroxidation, not only promotes insulin resistance [17], but also mediates
cholesterol and triglyceride metabolism [18]. It promotes necroinflammation, fibrogenesis, hepatic insulin resistance, and apoptosis [19]. Both serum and hepatic level of TNF-\(\alpha\) are elevated in patients with NAFLD [20, 21], and levels correlate with histological severity [22]. Conversely, inhibition of TNF-\(\alpha\) signaling improves IR and histological parameters of NAFLD [23, 24].

PPAR\(\gamma\) is one subtype of the three PPARs; the others are PPAR\(\beta/\delta\). PPAR\(\gamma\) agonists can promote adipose tissue to absorb and store FFAs and meanwhile inhibit liver fatty acid synthesis [25] via activating the AMP activated protein kinase (AMPK), of which the synthetic PPAR\(\gamma\) ligand (TZDS) has been used in the treatment of diabetes for many years. PPAR\(\gamma\) not only has anti-inflammatory effects, but also can effectively improve insulin resistance [8]. The activation of PPAR\(\gamma\) in immune system modulates inflammatory response [26]. In recent years, scholars have found that there were obvious changes in liver fat, increased adiponectin, and decreased TNF-\(\alpha\), IL-6, and resistin in patients with NAFLD after giving PPAR\(\gamma\) agonist treatment [27]. PPAR\(\gamma\) has been an important endogenous regulator and potential therapeutic target for nutritional NAFLD [28], of which the selective agonist [15] and an insulin-sensitizing agent [29] rosiglitazone has been a focus of treating NAFLD [30, 31].

High-fat diet induced animal model of NAFLD has been widely used to identify the pathogenesis and evaluate new treatments for NAFLD [32, 33]. In the present study, we have demonstrated that eight weeks of high-fat diet feeding induced fatty liver disease in SD rats, revealing key biochemical features of NAFLD, including increased elevation of hepatic enzymes, hyperinsulinaemia, hyperlipidaemia associated with increased TG accumulation in the liver, and

Figure 4: The results of frozen section and Oil Red O staining in vivo, \(\times400\). The red blots show lipid drops in hepatocytes. (a) Chow fed rat, (b) HFD model rats, (c) GGQLDL treatment rats, (d) GGQLDH treatment rats, and (e) ROS treatment rats.
histological changes containing steatosis, lobular and portal inflammation, and hepatocyte injury as ballooning, all about which reflected the characteristics of MetS [34]. Meanwhile, the histological abnormalities by H&E and ORO stains on the liver samples in the HFD rats of this study were consistent with existing reports [32, 35].

There are no pharmacological agents that have been approved for the treatment of NAFLD. Therefore, most clinical efforts have been directed focusing on the components of metabolic syndrome, namely, obesity, diabetes, dyslipidemia, and hypertension. Other interventions are directed at specific pathways potentially involved in the pathogenesis of NAFLD, such as insulin resistance, oxidative stress, and proinflammatory cytokines [36].

Chinese herbal medicine has been proven to play an anti-inflammatory effect in many fields of diseases [37, 38] and has a broad scope of drug safety. In the present study, treatment with GGQLD for 8 weeks has been proven to significantly normalize the liver hepatic aminotransferase (ALT and AST) to a level as nearly normal as chow control group. What is more, it was effective in impeding fat infiltration, which is evidenced by decreased hepatic TG contents and lipid droplets. Although the pathogenic mechanisms of NAELD are still under investigation, fat accumulation, especially triglycerides filtration into hepatocytes, is considered in the first step in development of NAFLD [4]. Hence, lipid accumulation plays a vital role with no doubt in NAFLD. The results from biochemistry and histology assays showed that GGQLDL and rosiglitazone produced an effect of reducing serum LDL-C and TC, respectively. Meanwhile, HDL-C level rose and TC decreased in GGQLDH group. What is more, histological stains showed GGQLDs and rosiglitazone decreased lipids droplets in hepatocytes and normalized steatosis in HFD rats. Overexpression of TNF-α has been identified and can mediate macrophage infiltration locally and at distant sites, such as liver. What is more, hepatic inflammation resulting from adipose proinflammatory cytokines does play an important role in the development of NAFLD [39].
The present study detected serum and liver TNF-α by biochemical method. The serum TNF-α level increased in HFD group was shown in the present study, while decreasing in GGQLD and rosiglitazone groups. Besides, the expression of PPARγ protein and gene was also measured. The protein and gene expression in HFD rats decreased compared to chow group. Remarkably, GGQLD made a great contribution to increasing PPARγ protein and gene expression, with the equal effects in rosiglitazone group, which approved the effect of GGQLD on treating NAFLD. Puerarin, for example, has antioxidative and anti-inflammatory activity [43] and can exhibit therapeutic effect on NAFLD by antioxidation, lowering cholesterol, and improving leptin signal transduction [44, 45], while berberine improves glucose metabolism by inhibition of hepatic gluconeogenesis [46] and reduces methylation of the microsomal triglyceride transfer protein promoter in fatty liver [42].

Thus, based on the data in the present study, GGQLD had a positive intervention on NAFLD through improving lipid regulation and inflammation, which gave more lab data to support its clinical use. Because the medicine herals in GGQLD have been used in traditional Chinese medicine (TCM) for thousand years, GGQLD has been considered for its safety and tolerability. This study explored that GGQLD is an optimal approach to NAFLD through managing lipid metabolic, inflammatory, and histological abnormalities via PPARγ/TNF-α pathway. Further experiments would focus on systematic molecular mechanisms of GGQLD, using different blocking agents and advanced experimental techniques.

**Abbreviations**

GGQLD: Gegenqinliand decoction
NAFLD: Nonalcoholic fatty liver disease
NASH: Nonalcoholic steatohepatitis
H&E: Haematoxylin and Eosin
ORO: Oil Red O
References

[1] D. A. Sass, P. Chang, and K. B. Chopra, “Nonalcoholic fatty liver disease: a clinical review,” Digestive Diseases and Sciences, vol. 50, no. 1, pp. 171–180, 2005.

[2] M. Charlton, “Nonalcoholic fatty liver disease: a review of current understanding and future impact,” Clinical Gastroenterology and Hepatology, vol. 2, no. 12, pp. 1048–1058, 2004.

[3] R. VuppalaNanchi and N. Chalasani, “Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: selected practical issues in their evaluation and management,” Hepatology, vol. 49, no. 1, pp. 306–317, 2009.

[4] J. K. Dowman, J. W. Tomlinson, and P. N. Newsome, “Pathogenesis of non-alcoholic fatty liver disease,” QJM, vol. 103, no. 2, Article ID hcp158, pp. 71–83, 2009.

[5] M. Enjoji, K. Yasutake, M. Kohjiama, and M. Nakamuta, “Nutrition and nonalcoholic fatty liver disease: the significance of cholesterol,” International Journal of Hepatology, vol. 2012, Article ID 925807, 6 pages, 2012.

[6] C. Postic and J. Girard, “Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice,” The Journal of Clinical Investigation, vol. 118, no. 3, pp. 829–838, 2008.

[7] M. Kugelmas, D. B. Hill, B. Vivian, L. Marsano, and C. J. McClain, “Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E,” Hepatology, vol. 38, no. 2, pp. 413–419, 2003.

[8] A. Gastaldelli, Y. Miyazaki, A. Mahankali et al., “The effect of pioglitazone on the liver: role of adiponectin,” Diabetes Care, vol. 29, no. 10, pp. 2275–2281, 2006.

[9] C.-H. Zhang, G.-L. Xu, Y.-H. Liu et al., “Anti-diabetic activities of Gegen Qnlian Decoction in high-fat diet combined with streptozotocin-induced diabetic rats and in 3T-L1 adipocytes,” Phytomedicine, vol. 20, no. 3-4, pp. 221–229, 2013.

[10] X.-L. Tong, L.-H. Zhao, F.-M. Lian et al., “Clinical observations on the dose-effect relationship of gegen qin lian decoction on 54 out-patients with type 2 diabetes,” Journal of Traditional Chinese Medicine, vol. 31, no. 1, pp. 56–59, 2011.

[11] S. Song, M. Qiu, Y. Chu et al., “Berberine down-regulates cellular JNK and NF-κB activation and this may result in an inhibition of HSV replication,” Antimicrobial Agents and Chemotherapy, 2014.

[12] Q. Wu, H. Ye, Y.-Z. Zhu, M. Guo, X.-X. He, and X.-B. Zheng, “Protective effect of baicalin against LPS-induced intestinal injury,” Zhongguo Zhongyao Zazhi, vol. 38, no. 17, pp. 2854–2858, 2013.

[13] X. Yang, J. Yang, and H. Zou, “Baicalin inhibits IL-17-mediated joint inflammation in murine adjuvant-induced arthritis,” Clinical and Developmental Immunology, vol. 2013, Article ID 268065, 8 pages, 2013.

[14] N. C. Chavez-Tapia, N. Rosso, and C. Tiribelli, “Effect of intracellular lipid accumulation in a new model of non-alcoholic fatty liver disease,” BMC Gastroenterology, vol. 12, article 20, 2012.

[15] U. Edvardsson, M. Bergström, M. Alexandersson, K. Bamberg, B. Ljung, and B. Dahlöf, “Rosiglitazone (BRL49653), a PPARα-selective agonist, causes peroxisome proliferator-like liver effects in obese mice,” Journal of Lipid Research, vol. 40, no. 7, pp. 1177–1184, 1999.

[16] D. Cai, M. Yuan, D. F. Frantz et al., “Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB,” Nature Medicine, vol. 11, no. 2, pp. 183–190, 2005.

[17] M. Yuan, N. Konstantopoulos, J. Lee et al., “Reversal of obesity-and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta,” Science, vol. 293, no. 5535, pp. 1673–1677, 2001.

[18] H. Tilg and A. M. Diehl, “Cytokines in alcoholic and nonalcoholic steatohepatitis,” The New England Journal of Medicine, vol. 343, no. 20, pp. 1467–1467, 2000.

[19] S. K. Satapathy, S. Garg, R. Chauhan et al., “Beneficial effects of tumor necrosis factor-α inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis,” The American Journal of Gastroenterology, vol. 99, no. 10, pp. 1946–1952, 2004.

[20] J. W. Haukeland, J. K. Damås, Z. Konopski et al., “Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2,” Journal of Hepatology, vol. 44, no. 6, pp. 1167–1174, 2006.

[21] J. M. Hui, A. Hodge, G. C. Farrell, J. G. Kench, A. Kriketos, and J. George, “Beyond insulin resistance in NASH: TNF-α or adiponectin?” Hepatology, vol. 40, no. 1, pp. 46–54, 2004.

[22] J. Crespo, A. Cayoena, P. Fernandez-Gil et al., “Gene expression of tumor necrosis factor α and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients,” Hepatology, vol. 34, no. 6, pp. 1158–1163, 2001.

[23] L. A. Adams, C. O. Zein, P. Angulo, and K. D. Lindor, “A pilot trial of pentoxifylline in nonalcoholic steatohepatitis,” American Journal of Gastroenterology, vol. 99, no. 12, pp. 2365–2368, 2004.

[24] Z. Li, S. Yang, H. Lin et al., “Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease,” Hepatology, vol. 37, no. 2, pp. 343–350, 2003.

[25] J. D. Browning and J. D. Horton, “Molecular mediators of hepatic steatosis and liver injury,” Journal of Clinical Investigation, vol. 114, no. 2, pp. 147–152, 2004.
[26] Y. Liu, J. Shi, J. Lu et al., “Activation of peroxisome proliferator-activated receptor-y potentiates pro-inflammatory cytokine production, and adrenal and somatotropic changes of weaned pigs after Escherichia coli lipopolysaccharide challenge,” *Innate Immunity*, vol. 15, no. 3, pp. 169–178, 2009.

[27] R. Belfort, S. A. Harrison, K. Brown et al., “A placebo–controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis,” *The New England Journal of Medicine*, vol. 355, no. 22, pp. 2297–2307, 2006.

[28] C. W. Wu, E. S. H. Chu, C. N. Y. Lam et al., “PPARy is essential for protection against nonalcoholic steatohepatitis,” *Gene Therapy*, vol. 17, no. 6, pp. 790–798, 2010.

[29] L. B. van Wagner and M. E. Rinella, “The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis,” *Therapeutic Advances in Gastroenterology*, vol. 4, no. 4, pp. 249–263, 2011.

[30] S. Liu, H.-J. Wu, Z.-Q. Zhang et al., “The ameliorating effect of rosiglitazone on experimental nonalcoholic steatohepatitis is associated with regulating adiponectin receptor expression in rats,” *European Journal of Pharmacology*, vol. 650, no. 1, pp. 384–389, 2011.

[31] V. Ratziu, P. Giral, S. Jacqueminet et al., “Rosiglitazone for non-alcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial,” *Gastroenterology*, vol. 135, no. 1, pp. 100–110, 2008.

[32] R. Barbuio, M. Milanski, M. B. Bertolo, M. J. Saad, and L. A. Veloso, “Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high–fat diet,” *Journal of Endocrinology*, vol. 194, no. 3, pp. 539–550, 2007.

[33] V. T. Samuel, Z.-X. Liu, X. Qu et al., “Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease,” *The Journal of Biological Chemistry*, vol. 279, no. 31, pp. 32345–32353, 2004.

[34] K.-X. Gan, C. Wang, J.-H. Chen, C.-J. Zhu, and G.-Y. Song, “Mitofusin-2 ameliorates high-fat diet-induced insulin resistance in liver of rats,” *World Journal of Gastroenterology*, vol. 19, no. 10, pp. 1572–1581, 2013.

[35] J. C. Fraulob, R. Ogg-Diamantino, C. Fernandes-Santos, M. B. Aguilera, and C. A. Mandarim-de-Lacerda, “A mouse model of metabolic syndrome: insulin resistance, fatty liver and Non-Alcoholic Fatty Pancreas Disease (NAFPD) in C57BL/6 mice fed a high fat diet,” *Journal of Clinical Biochemistry and Nutrition*, vol. 46, no. 3, pp. 212–223, 2010.

[36] B. Lam and Z. M. Younossi, “Review: treatment options for nonalcoholic fatty liver disease,” *Therapeutic Advances in Gastroenterology*, vol. 3, no. 2, pp. 121–137, 2010.

[37] S. Bose and H. Kim, “Evaluation of in vitro anti-inflammatory activities and protective effect of fermented preparations of rhizoma atractylodis macrocephalae on intestinal barrier function against lipopolysaccharide insult,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2013, Article ID 363076, 16 pages, 2013.

[38] L. Wang, X.-M. Qiu, Q. Hao, and D.-J. Li, “Anti-inflammatory effects of a chinese herbal medicine in atherosclerosis via estrogen receptor β mediating nitric oxide production and NF-kB suppression in endothelial cells,” *Cell Death and Disease*, vol. 4, no. 3, p. e551, 2013.

[39] F. Tacke, T. Luedde, and C. Trautwein, “Inflammatory pathways in liver homeostasis and liver injury,” *Clinical Reviews in Allergy and Immunology*, vol. 36, no. 1, pp. 4–12, 2009.

[40] N. Ghosh, R. Ghosh, V. Mandal, and S. C. Mandal, “Recent advances in herbal medicine for treatment of liver diseases,” *Pharmaceutical Biology*, vol. 49, no. 9, pp. 970–988, 2011.

[41] P. Zheng, G. Ji, Z. Ma et al., “Therapeutic effect of puerarin on non-alcoholic rat fatty liver by improving leptin signal transduction through JAK2/STAT3 pathways,” *The American Journal of Chinese Medicine*, vol. 37, no. 1, pp. 69–83, 2009.

[42] X. Chang, H. Yan, J. Fei et al., “Berberine reduces methylation of the MTTP promoter and alleviates fatty liver induced by a high–fat diet in rats,” *Journal of Lipid Research*, vol. 51, no. 9, pp. 2504–2515, 2010.

[43] C. Xiao, J. Li, X. Dong et al., “Anti-oxidative and TNF-alpha suppressive activities of puerarin derivative (4AC) in RAW264.7 cells and collagen-induced arthritic rats,” *European Journal of Pharmacology*, vol. 666, no. 1–3, pp. 242–250, 2011.

[44] P. Zheng, G. Ji, Z. Ma et al., “Therapeutic effect of puerarin on non-alcoholic rat fatty liver by improving leptin signal transduction through JAK2/STAT3 pathways,” *The American Journal of Chinese Medicine*, vol. 37, no. 1, pp. 69–83, 2009.

[45] M. J. Chung, N.-J. Sung, C.-S. Park et al., “Antioxidative and hypocholesterolemic activities of water-soluble puerarin glycosides in HepG2 cells and in C57BL/6J mice,” *European Journal of Pharmacology*, vol. 578, no. 2-3, pp. 159–170, 2008.

[46] X. Xia, J. Yan, Y. Shen et al., “Berberine improves glucose metabolism in diabetic rats by inhibition of hepatic gluconeogenesis,” *PLoS ONE*, vol. 6, no. 2, Article ID e16556, 2011.